<DOC>
	<DOCNO>NCT01875718</DOCNO>
	<brief_summary>The study phase 1/2 study two part . In part 1 , primary objective ass pharmacokinetics UC1010 administer subcutaneously single dose healthy woman . The safety tolerability UC1010 also evaluate study part 1 . In part 2 , primary objective ass pharmacodynamic effect UC1010 premenstrual symptom woman Premenstrual Dysphoric Disorder ( PMDD ) give luteal phase menstrual cycle . The pharmacodynamic effect evaluate patient ' daily rating premenstrual symptom . In study part , two active treatment group compare one placebo group .</brief_summary>
	<brief_title>A Phase I/II Study Evaluate UC1010 Treatment Premenstrual Dysphoric Disorder ( PMDD )</brief_title>
	<detailed_description />
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<criteria>Part 1 Essentially healthy Part 2 Have PMDD accord DSMIV verify two menstrual cycle steroid hormonal treatment previous three month treatment psychopharmaceuticals treatment PMS history significant medical condition ongoing pregnant plan pregnancy within study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>